• gmp-verlag.de
  • GMP Compliance Adviser Login
  • Shopping cart
Stay informed!

You’d like to be regularly informed on the latest developments in Good Manufacturing Practices?

 

Subscribe to our free GMP Newsletter LOGFILE!

>>> REGISTER NOW

GMP Compliance Adviser

GMP in Practice: 24 chapters written by internationally renowned industry experts.

 

GMP Regulations: 8 chapters with the most important GMP guidelines and regulations.

 

Image

>>> READ MORE

Award for the
GMP Compliance Adviser

GMP knowledge that convinces.

Image

On 7 June 2016 Maas & Peither GMP Publishing has received a

SIPAward in the category
"Best New Success Story" and was awarded with the 3rd place.

The GMP MANUAL (now: GMP Compliance Adviser) impressed the jury with "Safe Drugs through Better GMP Understanding".


TOP 5 GMP Downloads

1. Questionnaire for preparing GMP-inspections
More than 650 typical questions related to audits and inspections.


2. GMP Fundamentals
A quick and comprehensive overview of the complex world of GMP.


3. GDP Audit Questionnaire
More than 700 questions with reference to regulations.


4. A Pharma Guide to Cleaning Validation
How to meet Agency Expectations and Establish Accepted Limits.


5. Data Integrity in the EU
Requirements for Quality Management Systems.


>>> More Downloads

News about GMP/cGMP

2018-05-22

Post-Brexit Agreement for UK's Pharmaceutical Industry Needed

The UK government must secure a post-Brexit deal for the pharmaceutical industry that ensures the closest possible regulatory alignment with the EU and the minimum border friction possible or risk harming patients and seeing the pharma sector losing its status as a world leader, say the Business, Energy and Industrial Strategy Committee of the UK parliament.

 

The Committee’s report, ‘The impact of Brexit on the pharmaceutical sector’ finds that leaving the EU without an agreement for the industry would diminish access to markets, including £11.9billion of exports and to more than 446million potential patients and consumers in the EU. British patients’ access to medicines would also be at risk, with nearly three-quarters of pharmaceutical imports coming from the EU.

Drug costs could be significantly impacted

The report concludes that the prospect of regulatory divergence from the European Medicines Agency (EMA) is the deepest concern for the industry, which would mean pharmaceutical companies needing to duplicate their facilities and roles across the UK and EU. Drug costs could be significantly impacted. A separate regime could impose extra costs of £45,000 for each new product released, making the UK an unattractive market for new and innovative medicines. While the Government has indicated its desire for continued cooperation, the Committee calls for a continued form of membership of the EMA as a priority, and recommends that the Government seek to retain a presence for the EMA in the UK after its relocation to Amsterdam.

Source:

UK Parliament - Business, Energy and Industrial Strategy Committee - News

Comments
No comment has yet been written about this news.